Key Highlights

  • A shareholder vote on a reverse split remains open until October 30.
  • Fiscal 2025 revenue was $1.93 million, down 79.24% from $9.29 million.
  • A 1-for-40 reverse split was announced on April 24, 2026.
  • A $5 million public offering closed on August 7.

iSpecimen Inc. (NASDAQ:ISPC), operator of an online marketplace connecting life-science researchers with biospecimen holders, has a shareholder vote on a reverse stock split open until October 30. The company has a market capitalisation of about $2.85 million. Alongside the vote, it has been raising capital and has proposed an acquisition of Foldlab AI assets, making this a period of significant change.

Latest Company Context

Revenue has fallen sharply: fiscal 2025 revenue was $1.93 million, down 79.24% from $9.29 million in 2024, and trailing twelve-month revenue is about $466,000. The net loss for 2025 is listed at $10.49 million. The company announced a 1-for-40 reverse split on April 24, 2026, closed a roughly $2.5 million private placement in May, and on August 7 closed a $5 million public offering of common stock and pre-funded warrants with E.F. Hutton as placement agent.

On September 29 it highlighted support for a hospital's validation of a new chemistry analyzer involving more than 1,700 specimens, and on August 20 reported completing a large international cancer research order. A proxy filed October 9 seeks votes on a further reverse split in a range of 1-for-10 to 1-for-100, financing share issuances and the Foldlab AI asset acquisition, according to the same source; the proxy itself was not read.

Key Business Drivers

The core issue is whether order flow can recover from a steep decline while the company funds operations through repeated equity raises, which dilute existing holders. A reverse split may help with Nasdaq listing requirements but does not change underlying value. The Foldlab AI deal could change the business mix. With 7 employees reported, the company operates with limited scale.

What Investors Should Watch

Investors may watch the October 30 voting outcome, filings describing the Foldlab transaction, any further offerings, and the next quarterly report, which should reveal cash and revenue trends. Nasdaq compliance communications are also relevant. Additional specimen orders and partnerships could potentially support revenue, but timing is uncertain.

A Shrinking Marketplace Business at a Point of Significant Change

iSpecimen's revenue has fallen sharply while the company raises capital, votes on another reverse split and proposes a Foldlab AI asset deal. The October 30 vote is the nearest decision point.